PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Van Cutsem, Eric
TI  - New Analysis of CRYSTAL Results Supports Patient Selection According to RAS Mutation Status to Maximize Benefit from CET Therapy
DP  - 2014 Nov 01
TA  - MD Conference Express
PG  - 9--10
VI  - 14
IP  - 22
4099  - http://mdc.sagepub.com/content/14/22/9.short
4100  - http://mdc.sagepub.com/content/14/22/9.full
AB  - The randomized Phase 3 Cetuximab Combined With Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer trial [CRYSTAL; Van Cutsem E et al. N Engl J Med 2009] investigated the efficacy and safety of cetuximab combined with a simplified regimen of leucovorin–5-flourouracil—irinotecan (FOLFIRI) for the initial treatment of metastatic colorectal cancer.